Analytical Data
-
Gene name
Gzmc
- Application
-
Alternative Names
B10 (Cytotoxic cell protease 2) (CCP2)
-
Species
Mouse
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P08882
-
Expression Region
21-248aa
-
Molecular Weight
32.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Gzmc, or Granzyme M, is a serine protease predominantly expressed by cytotoxic T lymphocytes and natural killer (NK) cells, playing a crucial role in the immune response against tumor cells and virus-infected cells. Research on Gzmc has gained significant attention due to its unique mechanisms of action, which differ from other granzymes, such as Granzyme A and Granzyme B. Unlike these granzymes, which primarily induce apoptosis through DNA fragmentation, Gzmc has been shown to target multiple cellular pathways, leading to varied effects, including promoting cell death and influencing inflammation. The therapeutic potential of Gzmc, particularly in cancer immunotherapy and infectious diseases, is a focal point of study, as understanding its structure and function can lead to novel treatment strategies. Recombinant Gzmc proteins are being explored for their ability to enhance immune responses and selectively eliminate malignant cells. Investigating the biochemical properties of Gzmc, including its substrate specificity and interactions with cellular components, is essential for developing effective approaches that harness its immune-modulating capabilities. Overall, the study of Gzmc and its recombinant forms is positioned at the intersection of immunology and therapeutic development, potentially paving the way for innovative treatments in oncology and other diseases where the immune system's role is crucial.
